Brown University floats its own bid for Care New England

Care New England, the second-largest hospital system in Rhode Island, has been in negotiations since last April for a sale to Boston-based Partners HealthCare. Now it has some new potential suitors: Brown University and Prospect Medical Holdings.

Brown president Christina Paxson said the university wants to team with Prospect to buy Care New England, arguing if Partners completes the acquisition, the cost of care would increase and Rhode Islanders wouldn’t be able to advocate for how their healthcare system is run.

“If the focal point of Rhode Island health care shifts to Boston, excellent physicians (many of them Brown-trained) could be less likely to choose Rhode Island as a place to practice,” she wrote, according to the Providence Journal. “In addition, the full economic benefits of a strong local academic health system—one that brings in federal grants, generates spin-off companies and creates new jobs in Rhode Island—would be lost, perhaps forever.”

Under Paxson’s proposed plan, Brown would acquire Care New England’s Women & Infants Hospital, while Prospect would take over Kent Hospital and “non-hospital assets,” with the status of Butler Hospital to be worked out later. The United Nurses and Allied Professionals union, however, quickly came out against the idea.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.